重新审视劣质和假药作为低收入和中等收入国家抗菌药物耐药性驱动因素的盲点。
Revisiting the blind spot of substandard and fake drugs as drivers of antimicrobial resistance in LMICs.
作者信息
Gulumbe Bashar H, Adesola Ridwan O
机构信息
Department of Microbiology, Faculty of Science, Federal University, Birnin Kebbi, Kebbi State.
Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
出版信息
Ann Med Surg (Lond). 2023 Feb 7;85(2):122-123. doi: 10.1097/MS9.0000000000000113. eCollection 2023 Feb.
Abstract
One of the most significant risks to public health is ongoing antimicrobial resistance (AMR). Substandard and fraudulent medications, particularly in low- and middle-income countries (LMICs), are thought to have a role in the genesis and spread of AMR. There are numerous reports concerning the availability of subpar pharmaceuticals in developing countries, with no scientific evidence as to what exactly is included in some of the prescriptions supplied there. These counterfeit and inferior pharmaceuticals are a financial burden of up to US$200 billion, causing thousands of patient deaths, endangering both individual and public health,and undermining patient trust in the healthcare system. Poor quality and counterfeit antibiotics are often disregarded as possible causes of AMR in AMR studies. Therefore, we examined the issue of fake drugs in LMICs and its possible links to the emergence and spread of AMR.
摘要
对公众健康最大的风险之一是持续存在的抗菌药物耐药性（AMR）。劣质和假冒药品，尤其是在低收入和中等收入国家（LMICs），被认为在AMR的产生和传播中起到了作用。有许多关于发展中国家劣质药品供应情况的报告，但对于在那里提供的一些处方中究竟包含什么，没有科学证据。这些假冒和劣质药品造成了高达2000亿美元的经济负担，导致数千名患者死亡，危及个人和公众健康，并破坏患者对医疗系统的信任。在AMR研究中，质量差和假冒的抗生素通常被忽视，不被视为AMR的可能原因。因此，我们研究了低收入和中等收入国家假药问题及其与AMR出现和传播的可能联系。
相似文献
1
Revisiting the blind spot of substandard and fake drugs as drivers of antimicrobial resistance in LMICs.重新审视劣质和假药作为低收入和中等收入国家抗菌药物耐药性驱动因素的盲点。
Ann Med Surg (Lond). 2023 Feb 7;85(2):122-123. doi: 10.1097/MS9.0000000000000113. eCollection 2023 Feb.
2
Substandard and counterfeit medicines: a systematic review of the literature.不合格药品和假药：文献系统评价。
BMJ Open. 2013 Aug 17;3(8):e002923. doi: 10.1136/bmjopen-2013-002923.
3
Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines.应对不合格、伪造及未注册/未获许可的抗结核药品的全球影响。
J Med Access. 2022 Jan 23;6:23992026211070406. doi: 10.1177/23992026211070406. eCollection 2022 Jan-Dec.
4
Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?劣药和假药：被忽视的抗生素耐药性驱动因素？
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-008587.
5
Antimicrobial resistance in low- and middle-income countries: current status and future directions.中低收入国家的抗微生物药物耐药性：现状和未来方向。
Expert Rev Anti Infect Ther. 2022 Feb;20(2):147-160. doi: 10.1080/14787210.2021.1951705. Epub 2021 Jul 19.
6
Drivers of inappropriate antibiotic use in low- and middle-income countries.低收入和中等收入国家不适当使用抗生素的驱动因素。
JAC Antimicrob Resist. 2023 May 31;5(3):dlad062. doi: 10.1093/jacamr/dlad062. eCollection 2023 Jun.
7
Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence.假冒或不合格抗菌药物：科学证据综述
J Antimicrob Chemother. 2007 Aug;60(2):214-36. doi: 10.1093/jac/dkm109. Epub 2007 Jun 5.
8
Tackling Counterfeit Drugs: The Challenges and Possibilities.打击假药：挑战与可能性。
Pharmaceut Med. 2023 Jul;37(4):281-290. doi: 10.1007/s40290-023-00468-w. Epub 2023 May 15.
9
Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.发展中国家与不合格药品和假药相关的问题：一篇关于自由市场经济中抗逆转录病毒药物时代假药全球影响的综述文章。
East Afr J Public Health. 2008 Dec;5(3):205-10. doi: 10.4314/eajph.v5i3.39004.
10
Differential Drivers of Antimicrobial Resistance across the World.全球抗菌药物耐药性的差异驱动因素。
Acc Chem Res. 2019 Apr 16;52(4):916-924. doi: 10.1021/acs.accounts.8b00643. Epub 2019 Mar 8.
引用本文的文献
1
One Health: governance and regulatory framework for antimicrobial use in Malawi.一体化健康：马拉维抗菌药物使用的治理与监管框架
Sci One Health. 2025 Jul 19;4:100119. doi: 10.1016/j.soh.2025.100119. eCollection 2025.
2
Prevalence and determinants of multidrug-resistant uropathogenic Klebsiella species and associated antimicrobial resistance genes in Port Harcourt, Nigeria.尼日利亚哈科特港多重耐药性尿路致病性克雷伯菌属的流行情况、决定因素及相关抗菌药物耐药基因
BMC Infect Dis. 2025 Aug 18;25(1):1036. doi: 10.1186/s12879-025-11351-1.
3
Substandard and falsified antibiotics are associated with antimicrobial resistance: a retrospective country-level analysis.不合格及伪造抗生素与抗菌药物耐药性相关：一项国家级回顾性分析。
BMJ Glob Health. 2025 Jun 3;10(6):e017078. doi: 10.1136/bmjgh-2024-017078.
4
Knowledge, attitudes and practices of veterinarians and para-veterinarians towards antimicrobial stewardship in Malawi: underutilized strength in the fight against antimicrobial resistance.马拉维兽医和准兽医对抗菌药物管理的知识、态度和做法：对抗生素耐药性斗争中未得到充分利用的力量。
BMC Vet Res. 2025 May 30;21(1):390. doi: 10.1186/s12917-025-04837-2.
5
Post-market quality assessment of antibiotics: findings from a cross-sectional study using standardised patients in Tabalong and Bekasi districts, Indonesia.抗生素上市后质量评估：一项在印度尼西亚塔巴隆区和勿加泗区使用标准化患者进行的横断面研究结果
BMJ Open. 2025 May 14;15(5):e087801. doi: 10.1136/bmjopen-2024-087801.
6
Molecular and Epidemiological Characterization of ESBL-producing from Captive Wild Birds in Zoological Gardens in Nigeria.尼日利亚动物园圈养野生鸟类产超广谱β-内酰胺酶菌株的分子与流行病学特征
Environ Health Insights. 2025 Apr 27;19:11786302251329300. doi: 10.1177/11786302251329300. eCollection 2025.
7
Substandard antibiotics and their clinical outcomes among hospitalized patients in southern Malawi: a pilot study.马拉维南部住院患者中不合格抗生素及其临床结局：一项试点研究。
Front Pharmacol. 2025 Mar 18;16:1535501. doi: 10.3389/fphar.2025.1535501. eCollection 2025.
8
Investigation of CIP quality in over-the-counter drug stores of resource-limited countries: a comparative study in Vietnam and Nigeria.资源有限国家非处方药药店的药品不良反应监测质量调查：越南和尼日利亚的比较研究
JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf042. doi: 10.1093/jacamr/dlaf042. eCollection 2025 Apr.
9
The impact of the exodus of big pharmaceutical companies from Nigeria on antimicrobial resistance in the West African subregion.大型制药公司撤离尼日利亚对西非次区域抗菌药物耐药性的影响。
BMC Glob Public Health. 2024 May 24;2(1):35. doi: 10.1186/s44263-024-00068-z.
10
Understanding the veterinary antibiotic flow in Malawi: complexities, gaps and needs.了解马拉维的兽用抗生素流动情况：复杂性、差距与需求。
Front Vet Sci. 2024 Nov 20;11:1474307. doi: 10.3389/fvets.2024.1474307. eCollection 2024.
本文引用的文献
1
Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?劣药和假药：被忽视的抗生素耐药性驱动因素？
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-008587.
2
The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists.药剂师针对不合格和伪造药品进行全面多学科培训的必要性。
BMJ Glob Health. 2019 Jul 18;4(4):e001681. doi: 10.1136/bmjgh-2019-001681. eCollection 2019.
3
Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.识别不合格和假药的市场风险：基于中国、印度尼西亚、土耳其和罗马尼亚定性研究的分析框架。
Wellcome Open Res. 2019 Apr 16;4:70. doi: 10.12688/wellcomeopenres.15236.1. eCollection 2019.
4
Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.中低收入国家不合格和假冒药品的流行情况及经济负担估计：系统评价和荟萃分析。
JAMA Netw Open. 2018 Aug 3;1(4):e181662. doi: 10.1001/jamanetworkopen.2018.1662.
5
Substandard/counterfeit antimicrobial drugs.不合格/假冒抗菌药物。
Clin Microbiol Rev. 2015 Apr;28(2):443-64. doi: 10.1128/CMR.00072-14.
6
Blood culture isolates from children admitted to Medical Unit III, Yangon Children's Hospital, 1998.1998年仰光儿童医院第三内科收治儿童的血培养分离菌。
Southeast Asian J Trop Med Public Health. 2002 Dec;33(4):764-71.
7
Drug quality, a contributor to drug resistance?
Lancet. 1995 Jul 8;346(8967):122. doi: 10.1016/s0140-6736(95)92145-1.
Zotero 插件